Ignite Creation Date:
2025-12-24 @ 10:09 PM
Ignite Modification Date:
2025-12-25 @ 7:45 PM
Study NCT ID:
NCT04783935
Status:
COMPLETED
Last Update Posted:
2025-01-22
First Post:
2021-03-03
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-03-10
Start Date Type:
ACTUAL
Primary Completion Date:
2023-09-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-09-21
Completion Date Type:
ACTUAL
First Submit Date:
2021-03-03
First Submit QC Date:
None
Study First Post Date:
2021-03-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-09-20
Results First Submit QC Date:
None
Results First Post Date:
2025-01-22
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-09
Last Update Post Date:
2025-01-22
Last Update Post Date Type:
ACTUAL